Matthew Porteus, M.D., Ph.D. is a co-founder of Kamau Therapeutics as well as a pioneer in the field of gene editing. His work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients. Currently, he is the Sutardja Chuk Professor of Definitive and Curative Medicine in the department of pediatrics and section of pediatric stem cell transplantation, the co-director of the Center for Definitive and Curative Medicine at Stanford University, and co-executive director of the Stanford GMP (the Laboratory of Cell and Gene Medicine). Dr. Porteus’ work in gene editing spans more than 2 decades, during which he was an academic founder of CRISPR Therapeutics and Graphite Bio. In addition, he has served as an advisor to several other gene editing companies, as well as the National Heart, Lung, and Blood Institute on Sickle Cell Disease. As a trained pediatric stem cell transplant physician, he has over two decades of real world experience in the clinical aspects of hematopoietic stem cell transplantation. Finally, he is the academic sponsor of clinical trials, including those pioneering the application of non-chemotherapy based approaches to conditioning for HSCT’s.

‌Dr. Porteus’ research program at Stanford continues to focus on developing genome editing by homologous recombination as best in class curative therapies for patients with genetic and non-genetic diseases.